Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor is an
established therapy for a broad spectrum of patients with cardiovascular disease. The …

Stable coronary artery disease (CAD) has recently been replaced by a new entity described
as chronic coronary syndrome (CCS). This new entity has been developed based on a …

Background: The COMPASS trial (Cardiovascular Outcomes for People using
Anticoagulation Strategies) demonstrated that dual pathway inhibition (DPI) with …

Platelets participate centrally in atherothrombosis, resulting in vessel occlusion and
ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further …

Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …

Background Ticagrelor is a reversible oral P2Y12 platelet inhibitor used to treat patients with
acute coronary syndromes, prior myocardial infarction, high-risk coronary artery disease …

Patients with diabetes mellitus (DM) are characterized by enhanced thrombotic risk
attributed to multiple mechanisms including hyperreactive platelets, hypercoagulable status …

Dual antiplatelet therapy has long been the standard of care in preventing coronary and
cerebrovascular thrombotic events in patients with chronic coronary syndrome and acute …

Acute coronary syndrome (ACS) is principally driven by platelet aggregation. Dual
antiplatelet therapy (DAPT) has demonstrated a reduction in recurrent ischemic events. The …

Chronic coronary syndrome (CCS), which encompasses a broad spectrum of clinical
presentations of coronary artery disease (CAD), is the leading cause of morbidity and …